Updates are available Correction dated 2024-12-27

Article History

Received: 19 July 2024

Accepted: 2 October 2024

First Online: 16 October 2024

Change Date: 23 December 2024

Change Type: Update

Change Details: The original version of this article was revised: an important textual error was corrected in the fourth paragraph of Background section. The wording erroneously states that CETP inhibitors decreases Apo-E concentration instead of increasing effect as shown in reference [4]. The correct wording should read: However, all CETP inhibitors, including the novel CETP-inhibitor obicetrapib, increase plasma concentrations of apolipoprotein-E (Apo-E) [4], which is associated with decreased risk of dementia, in particular for Alzheimer’s disease (AD).

Change Date: 27 December 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1186/s13195-024-01639-w

Declarations

:

: The presented analyses exclusively sourced aggregated genetic data and did not analyse individual participants data. The underlying GWAS received appropriate ethical approval, please consult the individual publications. This research received approval by UCL Research Ethics Committee (UCL REC) under application number 27095/001, and was conducted in accordance with the Declaration of Helsinki.

: Not applicable.

: AFS and CF have received funding from New Amsterdam Pharma for this project. New Amsterdam Pharma is developing the CETP inhibitor Obicetrapib. MHD, MD, JK are employed by New Amsterdam Pharma, as chief executive officer, chief development officer, and chief scientific officer, respectively.